DNA vaccination against the ovarian carcinoma-associated antigen folate receptor α (FRα) induces cytotoxic T lymphocyte and antibody responses in mice

Cancer Gene Therapy

Volumn 6, Issue 4, 1999, Pages 349-357

  Neglia, Francesca ^a   Orengo, Anna Maria ^a   Cilli, Michele ^a   Meazza, Raffaella ^a   Tomassetti, Antonella ^b   Canevari, Silvana ^b   Melani, Cecilia ^b   Colombo, Mario P ^b   Ferrini, Silvano ^a  

^a CENTRO DI BIOTECNOLOGIE AVANZATE   (Italy)

^b NATIONAL CANCER INSTITUTE   (Italy)

Author keywords

Antibodies; Cytotoxic T lymphocyte; DNA vaccination; Folate receptor a; Interleukin 2

Indexed keywords

CANCER ANTIBODY; CARRIER PROTEIN; CELL SURFACE RECEPTOR; DNA VACCINE; FOLATE BINDING PROTEIN; FOLATE-BINDING PROTEIN; PRIMER DNA;

ANIMAL; ARTICLE; BAGG ALBINO MOUSE; BIOSYNTHESIS; CYTOTOXIC T LYMPHOCYTE; FEMALE; GENE VECTOR; GENETIC TRANSDUCTION; IMMUNOLOGY; INTRAMUSCULAR DRUG ADMINISTRATION; LUNG TUMOR; METASTASIS; MOUSE; NUCLEOTIDE SEQUENCE; OVARY TUMOR; PATHOLOGY; SPLEEN;

ANIMALS; ANTIBODIES, NEOPLASM; BASE SEQUENCE; CARRIER PROTEINS; DNA PRIMERS; FEMALE; GENETIC VECTORS; INJECTIONS, INTRAMUSCULAR; LUNG NEOPLASMS; MICE; MICE, INBRED BALB C; OVARIAN NEOPLASMS; RECEPTORS, CELL SURFACE; SPLEEN; T-LYMPHOCYTES, CYTOTOXIC; TRANSDUCTION, GENETIC; VACCINES, DNA;

EID: 0033163320     PISSN: 09291903     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.cgt.7700053     Document Type: Article

References (42)

1. Tang D, De Vit M, Johnston SA. Genetic immunization is a simple method for eliciting an immune response. Nature. 1992;356:152-154.
2. Fynan EF, Webster RG, Fuller DH, Haynes JR, Santoro JC, Robinson HL. DNA vaccines: protective immunizations by parental, mucosal, and gene-gun inoculations. Proc Natl Acad Sci USA. 1993;90:11478-11482.
3. Ertl HCJ, Xiang Z. Novel vaccine approaches. J Immunol. 1996;156:3579-3582.
4. Ulmer JB, Donnelly JJ, Parker SE, et al. Heterologous protection against influenza by injection of DNA encoding a viral protein. Science. 1993;259:1743-1748.
5. Wolff JA, Malone RW, Williams P, et al. Direct gene transfer into mouse muscle in vivo. Science. 1990;247: 1465-1468.
6. McDonnell WM. Askari FKDNA vaccine. N Engl J Med. 1996;334:42-45.
7. Kumar V, Sercarz E. Genetic vaccination: the advantages of going naked. Nat Med. 1996;2:857-859.
8. Tascon RE, Colston MJ, Ragno S, Stavropoulos E, Gregory D, Lowrie DB. Vaccination against tuberculosis by DNA injection. Nat Med. 1996;2:888-892.
9. Huygen K, Content J, Denis O, et al. Immunogenicity and protective efficacy of a tuberculosis DNA vaccine. Nat Med. 1996;2:893-898.
10. Gerloni M, Ripley Ballou W, Billetta R, Zanetti M. Immunity to Plasinodium falciparum malaria sporozoites by somatic transgene immunization. Nat Biotechnol. 1997; 15:876-880.
11. Wang B, Ugen KE, Srikantan V, et al. Gene inoculation generates immune responses against human immunodeficiency virus type 1. Proc Natl Acad Sci USA. 1993;90:4156-4160.
12. Kennedy RC. DNA vaccination for HIV. Nat Med. 1997; 3:501-502.
13. Boyer JD, Ugen KE, Wang B, et al. Protection of chimpanzees from high-dose heterologous HIV-1 challenge by DNA vaccination. Nat Med. 1997;3:526-532.
14. Bright RK, Beames B, Shearer MH, Kennedy RC. Protection against a lethal tumor challenge with SV40-transformed cells by the direct injection of DNA-encoding SV40 large tumor antigen. Cancer Res. 1996;56:1126-1130.
15. Conry RM, LoBuglio AF, Curiel DT. Polynucleotide-mediated immunization therapy of cancer. Semin Oncol. 1996;23:135-147.
16. Rosato A, Zambon A, Milan G, et al. CTL response and protection against P815 tumor challenge in mice immunized with DNA expressing the tumor-specific antigen P815A. Hum Gene Ther. 1997;8:1451-1458.
17. Baselga J, Mendelsohn J. The epidermal growth factor receptor as a target for therapy in breast carcinoma. Breast Cancer Res Treat. 1994;29:127-138.
18. Alberti S, Miotti S, Fornaro M, et al. The Ca-MOv18 molecule, a cell-surface marker of human ovarian carcinomas, is anchored to the cell membrane by phosphatidylinositol. Biochem Biophys Res Commun. 1990;171:1051-1055.
19. Coney LR, Tomassetti A, Carayannopoulos L, et al. Cloning of a tumor-associated antigen: MOv18 and MOv19 antibodies recognize a folate-binding protein. Cancer Res. 1991;51:6125-6132.
20. Campbell IG, Jones TA, Foulkes WD, Trowsdale J. Folate-binding protein is a marker for ovarian cancer. Cancer Res. 1991;51:5329-5338.
21. Ross JF, Chaudhuri PK, Ratnam M. Differential regulation of folate receptor isoforms in normal and malignant tissues in vivo and in established cell lines: physiologic and clinical implications. Cancer. 1994;73:2432-2443.
22. Weitman SD, Lark RH, Coney LR, et al. Distribution of the folate receptor GP38 in normal and malignant cell lines and tissues. Cancer Res. 1992;52:3396-3401.
23. Mantovani LT, Miotti S, Menard S, et al. Folate-binding ; protein distribution in normal tissues and biological fluids from ovarian carcinoma patients as detected by the monoclonal antibodies MOv18 and MOv19. Eur J Cancer. 1994;30A:363-369.
24. Miotti S, Canevari S, Menard S, et al. Characterization of human ovarian carcinoma-associated antigens defined by novel monoclonal antibodies with tumor-restricted specificity. Int J Cancer. 1987;39:297-303.
25. Toffoli G, Cernigoi C, Russo A, Gallo A, Bagnoli M, Boiocchi M. Overexpression of folate-binding protein in ovarian cancers. Int J Cancer. 1997;74:193-198.
26. 131I-MOv18: clinical results in patients with minimal residual disease of ovarian cancer. Eur J Cancer. 1995;31A:686-690.
27. Canevari S, Stoter G, Arienti F, et al. Regression of advanced ovarian carcinoma by intraperitoneal treatment with autologous T lymphocytes retargeted by a bispecific monoclonal antibody. J Natl Cancer Inst. 1995;87:1463-1469.
28. Meazza R, Marciano S, Sforzini S, et al. Analysis of IL-2 receptor expression and of the biological effects of IL-2 gene transfection in small-cell lung cancer. Br J Cancer. 1996;74:788-795.
29. Ramakrishna V, Negri DR, Brusic V, et al. Generation and phenotypic characterization of new human ovarian cancer cell lines with the identification of antigens potentially recognizable by HLA-restricted cytotoxic T cells. Int J Cancer. 1997;73:143-150.
30. Ferrini S, Biassoni R, Moretta A, Bruzzone M, Nicolin A, Moretta L. Clonal analysis of T lymphocytes isolated from ovarian carcinoma ascitic fluid: phenotypic and functional characterization of T cell clones capable of Iysing autologous carcinoma cells. Int J Cancer. 1985;36:337-343.
31. + cytotoxic lymphocytes. Cancer Res. 1997;57:87-93.
32. Geissler M, Wands G, Gesien A, de la Monte S, Bellet D, Wands JR. Genetic immunization with the free human chorionic gonadotropin β subunit elicits cytotoxic T lymphocyte responses and protects against tumor formation in mice. Lab Invest. 1997;76:859-871.
33. Boon T, Gajewski TF, Coulie PG. From defined human tumor antigens to effective immunization? Immunol Today. 1995;16:334-336.
34. Boon T, van der Bruggen P. Human tumor antigens recognized by T lymphocytes. J Exp Med. 1996;183:725-729.
35. Schreurs MW, de Boer AJ, Figdor CG, Adema GJ. Genetic vaccination against the melanocyte lineage-specific antigen gp100 induces cytotoxic T lymphocyte-mediated tumor protection. Cancer Res. 1998;58:2509-2514.
36. Gates SB, Mendelsohn LG, Shackelford KA, et al. Characterization of folate receptor from normal and neoplastic murine tissue: influence of dietary folate on folate receptor expression. Clin Cancer Res. 1996;2:1135-1141.
37. Tsuji T, Hamajima K, Ishii N, et al. Immunomodulatory effects of a plasmid expressing B7-2 on human immunodeficiency virus-1-specific cell-mediated immunity induced by a plasmid encoding the viral antigen. Eur J Immunol. 1997;27:782-787.
38. Kim JJ, Ayyavoo V, Bagarazzi ML, et al. In vivo engineering of a cellular immune response by coadministration of IL-12 expression vector with a DNA immunogen. J Immunol. 1997;158:816-826.
39. Iwasaki A, Stiernholm BJ, Chan AK, Berinstein NL, Barber BH. Enhanced CTL responses mediated by plasmid DNA immunogens encoding costimulatory molecules and cytokines. J Immunol. 1997;158:4591-4601.
40. Pisetsky DS. Immunostimulatory DNA: a clear and present danger? Nat Med. 1997;3:829-831.
41. Roman M, Martin-Orozco E, Goodman JS, et al. Immunostimulatory DNA sequences function as T helper-1-promoting adjuvants. Nat Med. 1997;3:849-854.
42. Romagnani S. The Th1/Th2 paradigm. Immunol Today. 1997;18:263-266.